Glutathione supplementation improves oxidative damage in experimental colitis

Area of Science:

• Gastroenterology
• Cell Biology
• Biochemistry

Background:

• Inflammatory bowel disease (IBD) pathogenesis involves increased free radicals and decreased mucosal antioxidant capacity.
• Oxidative stress plays a significant role in the development of colonic mucosal damage.

Purpose of the Study:

• To investigate the efficacy of parenteral glutathione administration in mitigating oxidative damage in a rat model of trinitrobenzenesulfonic acid (TNBS)-induced colitis.
• To evaluate glutathione's effects during both the onset and chronic phases of colitis.

Main Methods:

• Rats with TNBS-induced colitis were treated with glutathione (200 mg/kg once, or 50 mg/kg daily) or saline.
• Evaluated macroscopic and histological damage, and mucosal levels of lipoperoxides, malonyldialdehyde, glutathione, and cysteine.
• Assessed effects at 1 hour post-treatment (acute phase) and at 1, 2, 4, and 8 weeks (chronic phase).

Main Results:

• In the acute phase, glutathione pre-treatment significantly reduced histological scores and markers of lipid peroxidation (lipoperoxides, malonyldialdehyde).
• In the chronic phase, TNBS colitis led to reduced mucosal glutathione and cysteine, and increased lipid peroxidation.
• Glutathione supplementation in the chronic phase significantly improved colonic damage, restored endogenous antioxidant levels, and reduced lipid peroxidation.

Conclusions:

• Parenteral glutathione administration is effective in ameliorating oxidative colonic damage in a rat model of colitis.
• The findings support the role of oxidant/antioxidant imbalance in the pathogenesis of mucosal colonic injury.
• Glutathione supplementation represents a potential therapeutic strategy for inflammatory bowel disease.